Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Shelley Wood

September 20, 2021

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

Caitlin E. Cox

May 14, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Acoramidis Approved in Europe for ATTR Cardiomyopathy

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

FDA Approves TriClip TEER Device for Tricuspid Repair

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content